OxThera: A two-for-one offer

By concentrating on two forms of a single indication for which no therapeutics are available and few are in development, OxThera AB is hoping to corner the Orphan market for primary hyperoxaluria and maintain a role in the larger secondary hyperoxaluria indication.

Primary hyperoxaluria is a rare genetic disease affecting about 2,000 patients in the U.S. and Europe, resulting

Read the full 597 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE